Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias.
Four patients with chronic ventricular arrhythmias, shown to respond over the short term to N-acetylprocainamide (NAPA), were treated for between 3 and 4 yr with NAPA, and 24-hr ambulatory ECGs were obtained monthly to monitor their responses. When the patients were ambulatory and receiving NAPA, the mean frequency of premature ventricular complexes averaged 70% (range 60% to 82%) below that recorded at 6-mo intervals when the patients were hospitalized and receiving placebo. Analysis of variance showed that NAPA exerted an antiarrhythmic effect in these patients and that tolerance to this effect did not develop with long-term therapy. Plasma NAPA concentrations required to achieve this level of response averaged 21 micrograms/ml (12 to 35 micrograms/ml) and were roughly twice as high as those which appeared to be maximally effective when the patients were hospitalized for their initial evaluation. NAPA therapy was associated with positive antibody titers in only one patient and seems less prone to cause drug-induced lupus erythematosus than procainamide, but NAPA shares the gastrointestinal and other side effects of procainamide.
D000120:Acecainide / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000368:Aged; D000553:Ambulatory Care; D000704:Analysis of Variance; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000503:physiopathology; D002851:Chromatography, High Pressure Liquid; D004341:Drug Evaluation; D004562:Electrocardiography; D006207:Half-Life; D006352:Heart Ventricles; D006760:Hospitalization; D006801:Humans; D008134:Long-Term Care; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011342:Procainamide / Q000031:analogs & derivatives*; D013318:Stroke Volume
D000120:Acecainide; D011342:Procainamide